185 related articles for article (PubMed ID: 36609942)
1. Recombinant human chorionic gonadotropin and gonadotropin-releasing hormone agonist differently affect the profile of extracellular vesicle microRNAs in human follicular fluid.
Machtinger R; Racowsky C; Baccarelli AA; Bollati V; Orvieto R; Hauser R; Barnett-Itzhaki Z
J Assist Reprod Genet; 2023 Mar; 40(3):527-536. PubMed ID: 36609942
[TBL] [Abstract][Full Text] [Related]
2. Association between follicular fluid phthalate concentrations and extracellular vesicle microRNAs expression.
Barnett-Itzhaki Z; Knapp S; Avraham C; Racowsky C; Hauser R; Bollati V; Baccarelli AA; Machtinger R
Hum Reprod; 2021 May; 36(6):1590-1599. PubMed ID: 33885134
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.
Youssef MA; Van der Veen F; Al-Inany HG; Mochtar MH; Griesinger G; Nagi Mohesen M; Aboulfoutouh I; van Wely M
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD008046. PubMed ID: 25358904
[TBL] [Abstract][Full Text] [Related]
4. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
5. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
[TBL] [Abstract][Full Text] [Related]
6. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
[TBL] [Abstract][Full Text] [Related]
7. Urinary concentrations of phenols and phthalate metabolites reflect extracellular vesicle microRNA expression in follicular fluid.
Martinez RM; Hauser R; Liang L; Mansur A; Adir M; Dioni L; Racowsky C; Bollati V; Baccarelli AA; Machtinger R
Environ Int; 2019 Feb; 123():20-28. PubMed ID: 30481674
[TBL] [Abstract][Full Text] [Related]
8. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
[TBL] [Abstract][Full Text] [Related]
9. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Dual Trigger with Combination of Gonadotropin-Releasing Hormone Agonist and Human Chorionic Gonadotropin in İmproving Oocyte-Follicle Ratio in Normo-Responder Patients.
Gurbuz AS; Deveer R; Gode F
Niger J Clin Pract; 2021 Aug; 24(8):1159-1163. PubMed ID: 34397024
[TBL] [Abstract][Full Text] [Related]
11. Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve.
Lin MH; Wu FS; Hwu YM; Lee RK; Li RS; Li SH
Reprod Biol Endocrinol; 2019 Jan; 17(1):7. PubMed ID: 30609935
[TBL] [Abstract][Full Text] [Related]
12. Hormonal profile in early luteal phase after triggering ovulation with gonadotropin-releasing hormone agonist in high-responder patients.
Martazanova B; Mishieva N; Vedikhina I; Kirillova A; Korneeva I; Ivanets T; Abubakirov A; Sukhikh GT
Front Endocrinol (Lausanne); 2022; 13():834627. PubMed ID: 36046787
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin Releasing Hormone Agonist Final Oocyte Maturation and Human Chorionic Gonadotropin as Exclusive Luteal Support in Normal Responders.
Beck-Fruchter R; Baram S; Geslevich Y; Weiss A
Gynecol Obstet Invest; 2019; 84(1):27-34. PubMed ID: 30048969
[TBL] [Abstract][Full Text] [Related]
14. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
[TBL] [Abstract][Full Text] [Related]
15. Dual trigger with the combination of gonadotropin-releasing hormone agonist and standard dose of human chorionic gonadotropin improves
Mutlu I; Demirdag E; Cevher F; Erdem A; Erdem M
J Obstet Gynaecol; 2022 Jul; 42(5):1239-1244. PubMed ID: 34565274
[TBL] [Abstract][Full Text] [Related]
16. Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization.
Kim CH; Ahn JW; You RM; Kim SH; Chae HD; Kang BM
J Reprod Med; 2014; 59(1-2):63-8. PubMed ID: 24597289
[TBL] [Abstract][Full Text] [Related]
17. Early Follicular Phase Human Chorionic Gonadotropin Addition May Improve the Outcomes of
Zhang C; Wu F; Wu Z; Sun B; Chen C; Qian W
Front Endocrinol (Lausanne); 2021; 12():739773. PubMed ID: 34707571
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; Aboulfoutouh I; Khattab SM; van Wely M
Cochrane Database Syst Rev; 2011 Jan; (1):CD008046. PubMed ID: 21249699
[TBL] [Abstract][Full Text] [Related]
19. The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function.
Owens LA; Abbara A; Lerner A; O'floinn S; Christopoulos G; Khanjani S; Islam R; Hardy K; Hanyaloglu AC; Lavery SA; Dhillo WS; Franks S
Hum Reprod; 2018 Feb; 33(2):292-302. PubMed ID: 29206944
[TBL] [Abstract][Full Text] [Related]
20. Effect of Dual Trigger In Vitro Fertilization and Intracytoplasmic Sperm Injection During the Gonadotropin-releasing Hormone-Antagonist Cycle on Final Oocyte Maturation and Cumulative Live Birth Rate in Women with Diminished Ovarian Reserve.
Ren YM; Wang YB; Fu M; Zhang QX; Shen H; Han HJ; Gao FM
Curr Med Sci; 2022 Oct; 42(5):1066-1070. PubMed ID: 35997911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
